86797424 - EPIIOS

Information

• Trademark
• 86797424

• Source

• Serial Number

  86797424

• Registration Number

  5093926

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  October 23, 2015
  9 years ago

• Registration Date

  December 06, 2016
  8 years ago

• Transaction Date

  July 25, 2023
  a year ago

• Status Date

  June 16, 2023
  a year ago

• Published for Opposition Date

  September 20, 2016
  8 years ago

• Location Date

  December 06, 2016
  8 years ago

• Status Code

  710

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  DUBOIS, SUSAN L

• Attorney Docket Number

  Ferdiannd vo

  Attorney Name

  Weitnauer Rechtsanwälte

  Law Office Assigned Location Code

  M20

• Owners

  • EPIIOS THERAPEUTICS GMBH
  • IC DISCOVERY GMBH

Case File Statements

• GS0051: Dermatological pharmaceutical products; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical solutions used in dialysis; Pharmaceuticals, namely, psychotropics; Specialized tablets, capsules and powders for the delivery of pharmaceuticals sold without the pharmaceutical ingredient
• GS0011: Active chemical ingredients for use in the manufacture of anti-cancer drugs; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating human diseases of any kind; Chemical additives for use in the manufacture of pharmaceuticals; Chemical preparations for general industrial manufacturing; Chemical preparations, namely, silica based density centrifugation media, to be used in biochemical and clinical research; Chemicals for use in biotechnological product development; Chemicals for use in the biochemical and chemical industry; Chemicals, namely, buffer and standard solutions used in analytical chemistry; Industrial chemicals, namely, crosslinking coagents for thermoplastics; Reagents for use in scientific apparatus for chemical or biological analysis
• GS0421: Advanced product research in the field of artificial intelligence; Chemical, biochemical, biological and bacteriological research and analysis; Conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmology; Consulting services in the field of medical physics; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Laboratory research services relating to pharmaceuticals; Medical research services in the field of cancer; Pharmaceutical research and development; Pharmaceutical research services; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development of new products; Research and development of new products for others; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Technical research in the field of pharmaceutical studies

Case File Event Statements

• 6/16/2023 - a year ago

  23 - CANCELLED SEC. 8 (6-YR) Type: C8..

• 12/6/2021 - 3 years ago

  22 - COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Type: REM1

• 12/6/2016 - 8 years ago

  21 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 9/20/2016 - 8 years ago

  20 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 9/20/2016 - 8 years ago

  19 - PUBLISHED FOR OPPOSITION Type: PUBO

• 8/31/2016 - 8 years ago

  18 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 8/24/2016 - 8 years ago

  17 - AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Type: ASGN

• 8/18/2016 - 8 years ago

  16 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV

• 8/11/2016 - 8 years ago

  15 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 8/10/2016 - 8 years ago

  14 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 8/10/2016 - 8 years ago

  13 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 8/10/2016 - 8 years ago

  12 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 8/10/2016 - 8 years ago

  11 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 7/28/2016 - 8 years ago

  10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 7/28/2016 - 8 years ago

  9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 7/21/2016 - 8 years ago

  8 - ASSIGNED TO LIE Type: ALIE

• 7/19/2016 - 8 years ago

  7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 2/16/2016 - 8 years ago

  6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 2/16/2016 - 8 years ago

  5 - NON-FINAL ACTION E-MAILED Type: GNRT

• 2/16/2016 - 8 years ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 2/16/2016 - 8 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 10/28/2015 - 9 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 10/27/2015 - 9 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP